Skip to content
2000
Volume 26, Issue 9
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Introduction

Polypharmacy is frequently practiced in the management of schizophrenia due to its chronic nature, recurrent relapses, and associated comorbidities. While combining psychotropic medications may benefit patients with treatment-resistant symptoms, it poses risks such as drug–drug interactions (DDIs), adverse effects, and reduced medication adherence. The absence of uniform prescribing standards further complicates clinical decision-making.

Methods

This narrative review was conducted using a scoping methodology. Databases including PubMed, Scopus, and Web of Science were searched for English-language publications from 2000 to 2024. Search terms included “schizophrenia,” “polypharmacy,” “drug–drug interactions,” “clinical outcomes,” and “pharmacogenetics.” Eligible sources included clinical trials, observational studies, systematic reviews, and treatment guidelines. Exclusion criteria were non-English articles, gray literature, and individual case reports.

Results

Polypharmacy is reported in 30–60% of individuals with schizophrenia, especially in institutionalized or treatment-resistant populations. Treatment regimens often involve multiple antipsychotics along with adjunctive antidepressants or mood stabilizers. This approach is associated with increased risks of metabolic syndrome, cardiovascular events (., QT prolongation), extrapyramidal symptoms, and decreased adherence. Interindividual variability in pharmacogenetics further affects drug efficacy and safety. Innovative approaches like genotype-guided therapy and computerized clinical decision-support systems are promising but not yet widely implemented.

Discussion

Although polypharmacy may offer symptomatic relief in specific scenarios, it requires careful management due to its potential to cause harm. Rational prescribing, close monitoring, and attention to individual patient factors such as pharmacogenetic profiles are essential to optimize therapy.

Conclusion

Ensuring a balance between therapeutic benefit and adverse effects is crucial when employing polypharmacy in schizophrenia treatment. Integrating personalized medicine strategies, regular monitoring, and deprescribing practices when feasible can enhance clinical outcomes and patient safety.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002382047250930160449
2025-10-10
2026-02-24

  • From This Site

    /content/journals/cdm/10.2174/0113892002382047250930160449
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SuhailK. GhauriS. Phenomenology of delusions and hallucinations in schizophrenia by religious convictions.Ment. Health. Relig Cult201013324525910.1080/13674670903313722
     [Google Scholar]
  2. DoldM. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.Cochrane Database Syst. Rev.201511CD009831.Jan 16;10.1002/14651858.CD009831.pub225592299
     [Google Scholar]
  3. WalP. DwivediJ. WalA. VigH. SinghY. Detailed insight into the pathophysiology and the behavioral complications associated with the Parkinson’s disease and its medications.Future J. Pharm. Sci.2022813310.1186/s43094‑022‑00425‑5
     [Google Scholar]
  4. StrawnJ.R. StahlSM , Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD).Case Studies: Stahl’s Essential Psychopharmacology: Children and Adolescents.Cambridge University Press202325927810.1017/9781009049719.017
     [Google Scholar]
  5. BuckleyP.F. HwangM.Y. Comorbid psychiatric disorders in schizophrenia: More than just a chance co-occurrence.Obsessive-Compulsive Symptoms in Schizophrenia.Springer201531010.1007/978‑3‑319‑12952‑5_1
     [Google Scholar]
  6. Alba PaléL. Electroconvulsive therapy and psychotropic concomitant treatment: Study of clozapine and mood stabilizers.Eur. Neuropsychopharmacol.201626Suppl. 2S48010.1016/S0924‑977X(16)31485‑7
     [Google Scholar]
  7. AyanoG. Psychotropic medications metabolized by cytochromes P450 (CYP) 2D6 enzyme and relevant drug interactions.Clin. Pharmacol. Biopharm.20165410.4172/2167‑065X.1000162
     [Google Scholar]
  8. SmulevichA. RomanovD. Long-term course of negative symptoms in schizophrenia.Managing Negative Symptoms of Schizophrenia.Oxford Academic2020395010.1093/med/9780198840121.003.0003
     [Google Scholar]
  9. BudenholzerB. Review: In multiepisode schizophrenia, most antipsychotic drugs improve symptoms; adverse effects vary by drug.Ann. Intern. Med.201917110JC57. a10.7326/ACPJ201911190‑05731739340
     [Google Scholar]
  10. SamajdarS. TripathiS. Clinical pharmacological reconciliation, review and feedback in Ensuring Patient Safety.Authorea202310.22541/au.168318730.05878882/v1
     [Google Scholar]
  11. FerrarisA. AngrimanF. BarreraT. PenizzottoP. FaermanS. RivadeneiraW. ChiessaA. MuraG. PollánJ.A. SzmulewiczA.G. Prevalence of central nervous system-active polypharmacy in a cohort of older adults in Argentina.BJPsych Open2024106e19010.1192/bjo.2024.79839468835
     [Google Scholar]
  12. MuthannaF.M.S. IbrahimH.K. A descriptive retrospective study of the prevalence of antipsychotic polypharmacy (app) among schizophrenia patients in Malaysia.Research Square202210.21203/rs.3.rs‑1507228/v1
     [Google Scholar]
  13. JohnA.P. GeeT. AlexanderS. RamankuttyP. DragovicM. Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service.Australas. Psychiatry201422654655010.1177/103985621454667225147317
     [Google Scholar]
  14. MojtabaiR. OlfsonM. National trends in psychotropic medication polypharmacy in office-based psychiatry.Arch. Gen. Psychiatry2010671263610.1001/archgenpsychiatry.2009.17520048220
     [Google Scholar]
  15. CorrellC. Rummel-KlugeC. CorvesC. KaneJ. LeuchtS. Antipsychotic combinations versus monotherapy in schizophrenia: A meta-analysis of randomized controlled trials.Schizophr. Res.20081021-33510.1016/S0920‑9964(08)70110‑5
     [Google Scholar]
  16. KreyenbuhlJ.A. ValensteinM. McCarthyJ.F. GanoczyD. BlowF.C. Long-term antipsychotic polypharmacy in the VA health system: Patient characteristics and treatment patterns.Psychiatr. Serv.200758448949510.1176/ps.2007.58.4.48917412850
     [Google Scholar]
  17. GoffD.C. DixonL. Antipsychotic polypharmacy: Are two ever better than one?Am. J. Psychiatry2011168766766910.1176/appi.ajp.2011.1102031421724670
     [Google Scholar]
  18. TiihonenJ. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients.JAMA Psychiatry201710.26226/morressier.5971be85d462b80290b52546
     [Google Scholar]
  19. BarnesT.R.E. DrakeR. PatonC. CooperS.J. DeakinB. FerrierI.N. GregoryC.J. HaddadP.M. HowesO.D. JonesI. JoyceE.M. LewisS. Lingford-HughesA. MacCabeJ.H. OwensD.C. PatelM.X. SinclairJ.M.A. StoneJ.M. TalbotP.S. UpthegroveR. WieckA. YungA.R. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology.J. Psychopharmacol.202034137810.1177/026988111988929631829775
     [Google Scholar]
  20. NaberD. LambertM. Aripiprazole: A new atypical antipsychotic with a different pharmacological mechanism.Prog. Neuropsychopharmacol. Biol. Psychiatry20042881213121910.1016/j.pnpbp.2004.06.02015588748
     [Google Scholar]
  21. López-MuñozF. ÁlamoC. Active metabolites as antidepressant drugs: The role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders.Front. Psychiatry2013410210.3389/fpsyt.2013.0010224062697
     [Google Scholar]
  22. AmeerM.A. PatelP. SaadabadiA. Neuroleptic medications.StatPearls.StatPearls Publishing2024
     [Google Scholar]
  23. AyresJ.K. MaaniC.V. Milrinone.StatPearls.StatPearls Publishing2018
     [Google Scholar]
  24. GoodwinG. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.J. Psychopharmacol201630649555310.1177/026988111663654526979387
     [Google Scholar]
  25. RosenheckR.A. Open forum: effectiveness versus efficacy of second-generation antipsychotics: Haloperidol without anticholinergics as a comparator.Psychiatr. Serv.2005561859210.1176/appi.ps.56.1.8515637198
     [Google Scholar]
  26. DixonL.B. StroupT.S. Medications for first-episode psychosis: Making a good start.Am. J. Psychiatry2015172320921110.1176/appi.ajp.2014.1411146525727529
     [Google Scholar]
  27. BeaulieuJ.M. GainetdinovR.R. The physiology, signaling, and pharmacology of dopamine receptors.Pharmacol. Rev.201163118221710.1124/pr.110.00264221303898
     [Google Scholar]
  28. DoldM. FuggerG. AignerM. LanzenbergerR. KasperS. Dose escalation of antipsychotic drugs in schizophrenia: A meta-analysis of randomized controlled trials.Schizophr. Res.20151661-318719310.1016/j.schres.2015.04.02426008883
     [Google Scholar]
  29. McGlashanT.H. ZipurskyR.B. PerkinsD. AddingtonJ. MillerT. WoodsS.W. HawkinsK.A. HoffmanR.E. PredaA. EpsteinI. AddingtonD. LindborgS. TrzaskomaQ. TohenM. BreierA. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.Am. J. Psychiatry2006163579079910.1176/ajp.2006.163.5.79016648318
     [Google Scholar]
  30. SimpsonE.H. KellendonkC. KandelE. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia.Neuron201065558559610.1016/j.neuron.2010.02.01420223196
     [Google Scholar]
  31. GoossenR.B. FreemanD.J. SatchellA.M. UrquhartB.L. Monitoring clozapine.Ther. Drug Monit.200325446947210.1097/00007691‑200308000‑0000912883231
     [Google Scholar]
  32. SabéM. PallisK. SolmiM. CrippaA. SentissiO. KaiserS. Comparative effects of 11 antipsychotics on weight gain and metabolic function in patients with acute schizophrenia.J. Clin. Psychiatry202384222r1449010.4088/JCP.22r1449036752753
     [Google Scholar]
  33. LinJ.H. Transporter-mediated drug interactions: Molecular mechanisms and clinical implications.Drug-Drug Interactions.CRC Press201954556610.1201/9780429131967‑12
     [Google Scholar]
  34. PreskornS.H. Drug-Drug Interactions (ddis) in psychiatric practice, part 2: Strategies to minimize adverse outcomes from unintended ddis.J. Psychiatr. Pract.201824534134710.1097/PRA.000000000000033530427821
     [Google Scholar]
  35. HendsetM. MoldenE. KnapeM. HermannM. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.Ther. Drug Monit.2014361808510.1097/FTD.000000000000001824232129
     [Google Scholar]
  36. ChenW-Y. ShenY-C. Complex drug interaction of carbamazepine, fluvoxamine and clozapine in a patient with bipolar depression.Arch. Clin. Psychiatry201946617117110.1590/0101‑60830000000220
     [Google Scholar]
  37. WysokińskiA. Blood levels of glucose and insulin and insulin resistance in patients with schizophrenia on clozapine monotherapy.Diabetes Metab. Syndr.20148423624110.1016/j.dsx.2014.09.02025311817
     [Google Scholar]
  38. KearnsB. CooperK. CantrellA. PMU13 schizophrenia treatment with second-generation antipsychotics: A MULTI-country evaluation of the costs of cardiovascular and metabolic adverse events and weight gain.Value Health202023S60510.1016/j.jval.2020.08.1225
     [Google Scholar]
  39. MokN.S. LoY.K. TsuiP.T. LamC.W. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.J. Cardiovasc. Electrophysiol.200516121375137710.1111/j.1540‑8167.2005.00299.x16403073
     [Google Scholar]
  40. MasuoK. LambertW. Calcium channel blockers in obesity-related hypertension.Metab. Agents Med. Chem.2010102667510.2174/187152210793177027
     [Google Scholar]
  41. RanaA.Q. MorrenJ.A. Neuroleptic malignant syndrome (NMS).Neurological Emergencies in Clinical Practice.Springer201310911110.1007/978‑1‑4471‑5191‑3_13
     [Google Scholar]
  42. GardnerD.M. TeehanM.D. Tardive dyskinesia and other late-onset movement disorders.Antipsychotics and Their Side Effects.Cambridge University Press201012312810.1017/CBO9780511919237.023
     [Google Scholar]
  43. PuspitaO. ZulliesIkawati Antipsychotic-associated neuroleptic malignant syndrome (NMS) in schizophrenia patients: A narrative review.Indones J. Pharmacol. Ther.20245110.22146/ijpther.9878
     [Google Scholar]
  44. MitterauerB. Loss of function of glial gap junctions may cause severe cognitive impairments in schizophrenia.Med. Hypotheses200973339339710.1016/j.mehy.2009.04.00319435655
     [Google Scholar]
  45. SharifiH. HasanloeiM. MahmoudiJ. Polypharmacy-induced drug-drug interactions; Threats to patient safety.Drug Res.2014641263363710.1055/s‑0033‑136396524500732
     [Google Scholar]
  46. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia; American Psychiatric Association,202010.1176/appi.books.9780890424841
     [Google Scholar]
  47. BiglinoG. LaytonS. WrayJ. When we meet in a clearing: Making research accessible to patients and patient experience accessible to clinicians.J. Patient Exp.20196433333510.1177/237437351881944131853491
     [Google Scholar]
  48. CorrellC.U. Rummel-KlugeC. CorvesC. KaneJ.M. LeuchtS. Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials.Schizophr. Bull.200935244345710.1093/schbul/sbn01818417466
     [Google Scholar]
  49. RangnekarA.S. FontanaR.J. Managing drug-drug interactions with boceprevir and telaprevir.Clin. Liver Dis.201212364010.1002/cld.1031186844
     [Google Scholar]
  50. WalA. WalP. VigH. JainN.K. RathoreS. KrishnanK. SrivastavaA. Treatment of Parkinson’s disease: Current treatments and recent therapeutic developments.Curr. Drug Discov. Technol.2023205e12052321683410.2174/157016382066623051210034037183475
     [Google Scholar]
  51. PreskornS.H. Drug-Drug Interactions (ddis) in psychiatric practice, part 8: Relative receptor binding affinity as a way of understanding the differential pharmacology of currently available antidepressants.J. Psychiatr. Pract.2020261465110.1097/PRA.000000000000044531913969
     [Google Scholar]
  52. TaoD. WangH. XiaF. MaW. Pancytopenia due to possible drug-drug interactions between low-dose methotrexate and proton pump inhibitors.Drug Healthc. Patient Saf.202214757810.2147/DHPS.S35019435607639
     [Google Scholar]
  53. SalanderP. Including physiological variables in studies might confuse more than clarify.Patient Educ. Couns.201494114010.1016/j.pec.2013.08.02624051047
     [Google Scholar]
  54. SchwartzL.M. WoloshinS. The drug facts box: Making informed decisions about prescription drugs possible.Better Doctors, Better Patients, Better DecisionsMIT Press Direct201123324210.7551/mitpress/9143.003.0020
     [Google Scholar]
  55. DwivediJ. KaushalS. WalP. JCD. SharmaA. NathiyaD. GasmiA. A Data Mining Approach on Polypharmacy and Drug-drug Interactions of Common Diabetes Medications.Curr. Drug Metab.202510.2174/011389200235829125040119053340248924
     [Google Scholar]
  56. Patient lift manufacturer plans training video to augment Safety Alert.Biomed. Saf. Stand.1990202116310.1097/00149078‑199012010‑00003
     [Google Scholar]
  57. BousmanC.A. CYP2D6 testing to guide risperidone and aripiprazole therapy.Lancet Psychiatry20196536236410.1016/S2215‑0366(19)30138‑531000416
     [Google Scholar]
  58. BensonP.R. Factors associated with antipsychotic drug prescribing by southern psychiatrists.Med. Care198321663965410.1097/00005650‑198306000‑000066134878
     [Google Scholar]
  59. VerasR.P. Contemporary care model for older people: An urgent need.Rev. Bras. Geriatr. Gerontol.202023523006510.1590/1981‑22562022025.230065.en
     [Google Scholar]
  60. DimaA. WazirA. Clark-CastilloR. ZakopoulosI. SmithS. GaughranF. Factors influencing the length of stay in forensic psychiatric settings: A systematic review.BMC Health Serv. Res.202424140010.1186/s12913‑024‑10863‑x38553762
     [Google Scholar]
  61. RasT. HoldmanR. MatthewsD. Ramadhan fasting for people living with chronic illness: A narrative literature review.S. Afr. Fam. Pract.2024661e1e610.4102/safp.v66i1.580538299530
     [Google Scholar]
  62. LuoH. LauK.K. WongG.H.Y. ChanW.C. MakH.K.F. ZhangQ. KnappM. WongI.C.K. Predicting dementia diagnosis from cognitive footprints in electronic health records: A case–control study protocol.BMJ Open20201011e04348710.1136/bmjopen‑2020‑04348733444218
     [Google Scholar]
  63. PalermoS. Frailty in the elderly - Understanding and managing complexity.IntechOpen202210.5772/intechopen.83157
     [Google Scholar]
  64. KingsburyS.J. YiD. SimpsonG.M. Psychopharmacology: Rational and irrational polypharmacy.Psychiatr. Serv.20015281033103610.1176/appi.ps.52.8.103311474046
     [Google Scholar]
  65. DwivediJ. KumarP. SachanP. SinghC. SaxenaB. WalA. WalP. Phyto-pharmacological Potential of Aegle marmelos (L.) for neurological disorders: Progress and prospects.Recent Adv. Food Nutr. Agric.2024161123010.2174/012772574X28951724022204591638468524
     [Google Scholar]
  66. VerasR.P. Contemporary care model for the aged: An imminent need.Rev. Bras. Geriatr. Gerontol.202424123003810.1590/1981‑22562024027.230038.pt
     [Google Scholar]
  67. GoyalA. BerghS. EngedalK. KirkevoldM. KirkevoldØ. Norwegian version of the rating anxiety in dementia scale (RAID-N): A validity and reliability study.Aging Ment. Health201620910110910.1080/13607863.2016.122092127584559
     [Google Scholar]
  68. Pharmacists in Practice, Pharmacists are the success story of general practice, and they are here to stay.Pharm. J.2023310119010210.1211/pj.2023.1.190102
     [Google Scholar]
  69. KellyJ. Polypharmacy: Increasing medication adherence.Preprint202310.33015/dominican.edu/2023.NURS.RP.19
     [Google Scholar]
  70. BremanP. How automation technology may contribute to the quality of life in the elderly care: An integrated personalized care approach.Int. J. Integr. Care202121S121410.5334/ijic.ICIC20320
     [Google Scholar]
  71. AlbertsenN. SommerT.G. OlsenT.M. PrischlA. KallerupH. AndersenS. Polypharmacy and potential drug–drug interactions among Greenland’s care home residents.Ther. Adv. Drug Saf.2022132042098622110391810.1177/2042098622110391835784387
     [Google Scholar]
  72. FabbriC. ZoharJ. SerrettiA. Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials.Prog. Neuropsychopharmacol. Biol. Psychiatry201886364410.1016/j.pnpbp.2018.05.00729777729
     [Google Scholar]
  73. Higher-than-recommended doses of antipsychotic medications may not benefit people with schizophrenia and may increase side effects.PsycEXTRA Dataset200710.1037/e603782007‑025
     [Google Scholar]
  74. Access, cost, and quality issues in medication use.Preventing Medication Errors and Improving Drug Therapy Outcomes,10114510.1201/9780203010730‑12
     [Google Scholar]
  75. PardiñasA.F. OwenM.J. WaltersJ.T.R. Pharmacogenomics: A road ahead for precision medicine in psychiatry.Neuron2021109243914392910.1016/j.neuron.2021.09.01134619094
     [Google Scholar]
  76. WagnerE. LuykxJ.J. StrubeW. HasanA. Challenges, unmet needs and future directions – A critical evaluation of the clinical trial landscape in schizophrenia research.Expert Rev. Clin. Pharmacol.2024171111810.1080/17512433.2023.229399638087450
     [Google Scholar]
  77. SolmiM. MurruA. PacchiarottiI. UndurragaJ. VeroneseN. FornaroM. StubbsB. MonacoF. VietaE. SeemanM. CorrellC. CarvalhoA. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: A state-of-the-art clinical review.Ther. Clin. Risk Manag.20171375777710.2147/TCRM.S11732128721057
     [Google Scholar]
  78. PaulC. Innovations in medication therapy management: The role of artificial intelligence and digital health technologies.2023Available from: https://iipseries.org/assets/docupload/rsl20247558F1CECCB46B4.pdf.
/content/journals/cdm/10.2174/0113892002382047250930160449
Loading
The Intricacies of Polypharmacy and Drug Interactions in Schizophrenia Treatment
Current Drug Metabolism 26, 579 (2025); https://doi.org/10.2174/0113892002382047250930160449
/content/journals/cdm/10.2174/0113892002382047250930160449
/content/journals/cdm/10.2174/0113892002382047250930160449
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): antipsychotics; clinicaloutcomes; drug-drug interactions; pharmacogenetics; Polypharmacy; schizophrenia

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test